Xortx TherapeuticsXRTX
13F holders, Q4 2024 (December 31)6holders −1
1new positions
2sold out
$1.13avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, down 1 from Q3 2024. 1 opened new positions and 2 sold out. The largest holders were Armistice Capital, LLC ($299K), UBS Group AG ($20K) and Royal Bank of Canada ($2K).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $299K |
| Exits | 2 | $1K |
All 13F filers, Q3 2024 → Q4 2024: 265,821 shares bought and 3,517 shares sold, net +262,304 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Armistice Capital, LLC | 0.01% | New | 265,000 | $299K |
| UBS Group AG | 0.00% | Reduce -7.2% | 17,428 | $20K |
| Royal Bank of Canada | 0.00% | Add +122.2% | 1,493 | $2K |
| National Bank of Canada | 0.00% | Reduce -53.1% | 1,613 | $2K |
| Osaic Holdings, Inc. | 0.00% | No change | 1,153 | $1K |
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $313 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.